ClinicalTrials.gg
CompletedNCT00508365Updated Aug 9, 2017

Evaluation of Potential for Orthostatic Hypotension in Elderly Hypertensives

A Phase 1 interventional study of Carvedilol CR capsules and Placebo in Hypertension, sponsored by GlaxoSmithKline. Completed at 20 sites in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2017-08-09.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing lisinopril in Hypertension — none open to participants now, none under way, none of them phase 3. Lisinopril · Hypertension.

Enrollment
13th of 30
62 · median 55
Started
2007
with 5 others
Phase 1
7 of 30
none open now
Registered
9th of 30
by date
Lead sponsor
5 of 30
GlaxoSmithKline

Among the 30 studies testing lisinopril in Hypertension, this one is the 13th largest by enrollment, is one of 6 that started in 2007, is one of 7 in phase 1, and was the 9th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 30 studies testing lisinopril in Hypertension is open now. The open studies under Hypertension, anywhere →

About lisinopril

Lisinopril: first FDA approval 1987 (PRINIVIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 30 studies testing lisinopril in Hypertension as a file.
02

Study summary

This is a multi-center, double-blind, randomized, placebo-controlled, 2-session crossover study to evaluate the incidence of orthostatic hypotension in elderly hypertensive subjects following co-administration of carvedilol CR and lisinopril.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • lisinopril
  • carvedilol
  • hypertension
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females who are ≥ 65 years of age
  • (BMI) between 24 and 37 kg/m2 where: BMI = (weight in kg)/ (height in meters)2
  • Subjects must have a documented history of essential hypertension and must be stable on treatment with an ACE inhibitor or angiotensin II receptor antagonist or renin antagonist and no more than one other antihypertensive medication at least 3 months before screening with a sitting SBP\<180 mmHg and DBP\<110 mmHg.
  • All subjects must be able to be safely (in the opinion of the Investigator) withdrawn or down-titrated from all antihypertensive treatment(s) and transitioned to lisinopril 10 mg OD for the two-week run-in phase.

Exclusion criteria

Exclusion Criteria:

  • Any abnormality identified on the screening history, physical or laboratory examination, or any other medical condition or circumstance making the volunteer unsuitable for participation in the study
  • Subject who metabolizes carvedilol poorly based on CYP2D6 genotype as determined at screening
  • Subject has persistent hyperkalemia or history of hyperkalemia resulting from either Type IV RTA (renal tubular acidosis) or previous treatment with an ACE inhibitor, ARB or renin inhibitor.
  • Subject has malignant (accelerated) hypertension, history of malignant hypertension, or history of secondary forms of hypertension
  • Subject has advanced hypertensive retinopathy (Keith Wagner Grade IV)
  • Subject has a history of hepatic impairment (characterized by prolonged /low concentrations of albumin) and/or renal insufficiency (subjects with an estimated ≤ 30 mL/min by Cockroft-Gault must be excluded). CrCL = [140-ageCr][weight/70] x 0.85 (if female); Cr in mg/dL; Weight in kg
  • Subject is being treated for diabetes mellitus
  • Subject has a history of angioedema
  • Subject has been under treatment with 3 or more antihypertensive medications. (NOTE: A combination drug containing two antihypertensive agents represents two antihypertensive medications.)
  • Subject has been under treatment with HCTZ > 12.5 mg/day
  • Subject is receiving ongoing treatment or is anticipated to receive treatment with any of the following medications during the study:

    • monoamine oxidase inhibitors (MAO)
    • any Class I or III antiarrhythmic
    • alpha-adrenergic receptor blockers
    • beta-2-adrenergic agonists
    • all antidepressants including SSRIs
    • lithium
    • medications known to be inhibitors/inducers of cytochrome P-450 2D6 should be discontinued for at least 14 days or 5 half-lives [which ever is longer] prior to the first day of the run-in period
  • Treatment with any over-the-counter medications , herbal and dietary supplements, as well as grapefruit-containing products within 7 days or 5 half-lives (whichever is longer) prior to first day of run-in period through the end of the study unless approved by the PI and GSK medical monitor. Standard vitamins and/or daily multi-vitamins are permitted, however herbal vitamins should be excluded.
  • Treatment with an drug within 30 days or 5 half-lives (whichever is longer) preceding the run-in period
  • Subject has mean sitting SBP ≥ 180 mmHg at the screening assessment (one set of repeat measurement is permitted as per approval by the medical monitor).
  • Documented history of low blood pressure within six months of screening visit (average sitting SBP \< 110 mm Hg and/or DBP /\< 50 mm Hg) or blood pressure below these values at time of screening (one set of repeat measurement is permitted as per approval by the medical monitor).
  • Orthostatic hypotension diagnosed at screening (orthostatic hypotension is defined as a reduction in systolic blood pressure of 20 mmHg or more and/or a reduction in diastolic blood pressure of 10 mmHg or more for standing vs. supine measurements)
  • Subject has any of the following conditions:

    • uncontrollable or symptomatic arrhythmias; unstable angina
    • sick sinus syndrome or second or third degree heart block (unless treated with a permanent, functioning pacemaker)
    • bradycardia (seated heart rate \<55 bpm) (one repeat measurement is permitted as per approval by the medical monitor) ; history of myocardial infarction, or history of stroke within 1 year of screening.
    • subject is in, or has a history of atrial fibrillation
  • Any of the following abnormalities on 12-lead during screening:

    • complete RBBB or LBBB
    • evidence of second- or third-degree AV block
    • pathological Q-waves (Q-wave wider than 0.04 sec or depth greater than 0.4-0.5 mV)
    • any other abnormalities that investigator feels could be of concern when patient is taking a β-adrenergic blocking agent
  • Donation of blood in excess of 500 mL within a 56-day period including the estimated 150 mL of blood to be drawn during this study
  • History of asthma, and/or to β -adrenergic blocking agents
  • History of sensitivity to carvedilol, lisinopril, alpha-blockers, beta-blockers or ACE inhibitors
  • History of sensitivity to any of the study medications or components thereof
  • History of anaphylaxis or anaphylactoid reactions or severe allergic responses to drugs
  • History of regular alcohol consumption exceeding 7 drinks/week for women or 14 drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of screening
  • Unanticipated positive urine drug screen (UDS) at screening. Note: If the subject is taking a drug known to give a positive on the UDS, then this should be discussed with the medical monitor prior to sending the UDS. In this situation, with prior approval, a positive finding on the UDS will not be considered an exclusion
  • Positive for surface antigen or
  • Unwillingness or inability to follow the procedures outlined in the protocol or inability to provide written
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Subjects receiving treatment sequence AB

    Eligible subjects will receive treatment sequence AB; A= Placebo to match COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). Placebo to match COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14). B=COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14).

    Drug: Carvedilol CR capsules · Drug: Placebo · Drug: Lisinopril

  • Experimental
    Subjects receiving treatment sequence BA

    Eligible subjects will receive treatment sequence BA; B=COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14). A= Placebo to match COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). Placebo to match COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14).

    Drug: Carvedilol CR capsules · Drug: Placebo · Drug: Lisinopril

Interventions

  • DrugCarvedilol CR capsules

    The carvedilol micropump (COREG) CR cpsules will be available with doses of 20 milligrams and 40 milligrams administered orally once daily.

  • DrugPlacebo

    Placebo capsules to match each dose level will be provided.

  • Lisinopril will be available as 10 milligrams tablets administered orally once daily.

06

What researchers measure

Primary outcomes

  1. Assessment of orthostasis 6 hours post dose on day 1, 7, 8, 14 in each dosing session

    Time frame: 6 hours post dose on day 1, 7, 8, 14 in each dosing session

  2. To evaluate the incidence of orthostatic hypotension (defined as a decrease in SBP of ≥20 mmHg and/or a decrease in DBP of ≥10 mmHg in changing from the supine to the standing position) following co-administration of COREG CR and lisinopril

    Time frame: Up to Day 14

Secondary outcomes

  1. Relationship of concentration of drug to events 6 hours post dose on day 1, 7, 8, 14 in each dosing session

    Time frame: 6 hours post dose on day 1, 7, 8, 14 in each dosing session

  2. Relationship of concentration of drug to events

    Time frame: 6 hours post dose on day 1, 7, 8, 14 in each dosing session

  3. To evaluate the safety and tolerability of the co-administration of COREG CR and lisinopril

    Time frame: Up to Day 24

  4. To evaluate the relationship between the plasma concentrations of carvedilol and lisinopril and the occurrence of orthostatic hypotension following co-administration of COREG CR and lisinopril

    Time frame: 6 hours post dose on day 1, 7, 8, 14 in each dosing session

  5. To evaluate the effects of COREG CR on plasma renin activity

    Time frame: Up to Day 14

07

Study locations

20 sites
  • GSK Investigational Site
    Anniston, Alabama 36207, United States
  • GSK Investigational Site
    Glendale, Arizona 85308, United States
  • GSK Investigational Site
    Anaheim, California 92801, United States
  • GSK Investigational Site
    Beverly Hills, California 90211, United States
  • GSK Investigational Site
    Long Beach, California 90806, United States
  • GSK Investigational Site
    Coral Gables, Florida 33134, United States
  • GSK Investigational Site
    Miami, Florida 33169, United States
  • GSK Investigational Site
    Sarasota, Florida 34239, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33409, United States
  • GSK Investigational Site
    Boise, Idaho 83704, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46260, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89119, United States
  • GSK Investigational Site
    Hackensack, New Jersey 07601, United States
  • GSK Investigational Site
    Fargo, North Dakota 58103, United States
  • GSK Investigational Site
    Cleveland, Ohio 44122, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73132, United States
  • GSK Investigational Site
    Portland, Oregon 97239, United States
  • GSK Investigational Site
    Austin, Texas 78704, United States
  • GSK Investigational Site
    Houston, Texas 77081, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
08

References and documents

Publications

  • GSK has submitted manuscripts of these study results to peer-reviewed scientific journals which were not accepted for publication. GSK is providing the attached study results summary with a conclusion.

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2007 to primary completion in Jun 2008, 8 months.

Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 8 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2007
First posted
Jul 30, 2007
StartActual
Sep 25, 2007
Primary completionActual
Jun 3, 2008
CompletionActual
Jun 3, 2008
Last update
Aug 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00508365
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 30, 2007
Start date
Sep 25, 2007
Primary completion
Jun 3, 2008
Completion
Jun 3, 2008
Last update
Aug 9, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisinopril

Start the discussion